ClinicalTrials.gg
CompletedNCT03773042Updated Dec 13, 2018

A Study Evaluating Tolerability, Efficacy, and Safety of HSK3486 Injectable Emulsion in Patients

A Phase 2 interventional study of HSK3486 and Propofol in Colonoscopy, sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-12-13.

Sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Dec 2016, registered Dec 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A double-blind, randomized, active controlled, multi-center, parallel group study comparing HSK3486 with Propofol, in patients undergoing a colonoscopy.

02

Conditions studied

  • Colonoscopy
03

In context

Lead sponsor

Sichuan Haisco Pharmaceutical Group Co., Ltd is the lead sponsor of 30 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (those who meet all of the following are eligible)

  1. Patients requiring diagnostic colonoscopy with an estimated examination time ≤ 30 min; males and females, I-II, between 18 and 65 years old (inclusive);
  2. (BMI) ≥ 18 and ≤ 30 kg/m2
  3. Respiratory rate between ≥ 10 and ≤ 24 breaths per minute; SpO2 when inhaling > 95%; SBP ≥ 90 mmHg; DBP ≥ 60 mmHg; heart rate between ≥ 50 and ≤ 100 beats per minute;
  4. Subjects must understand the procedures and methods of this study, and be willing to provide and to complete the trial in strict accordance with clinical trial protocol.

Exclusion Criteria (those who meet any one of the following are ineligible):

  1. Patients having to general anesthesia or previous history of anesthesia accidents;
  2. Patients with a known sensitivity to propofol, opioids, naloxone, eggs, soy products or a medical condition such that these agents were contraindicated;
  3. Patient received any of the following drugs or therapies prior to screening:

    1. Participated in other drug clinical trials within 3 month prior to screening;
    2. In receipt of propofol and/or opioid analgesics within 1 month prior to screening;
  4. The patient has some history or evidence of increased risk of sedation or anesthesia, such as cardiovascular disease, respiratory disease, cerebrovascular disease, gastrodintestinal disease and other system disease prior to the screening and/or baseline period.
  5. Patient whose laboratory parameters measured at screening/prior to enrollment reach the following criteria and verified through re-examinations:

    1. ANC ≤ 1.5 x 109/L;
    2. ≤ 80 x 109/L;
    3. ≤ 90 g/L (no blood transfusion within the last 14 days);
    4. and ALT ≥ 2.5 x ;
    5. ≥ 1.5 x ULN;
    6. Creatinine ≥ 1.5 x ULN.
  6. History of alcohol abuse within 3 months prior to screening or with a positive result of alcohol saliva strip test (before dose);
  7. History of medication abuse within 3 months prior to screening, or a positive urine medication test (during screening or before dose administration);
  8. Women who are pregnant or breastfeeding; women of or men who are unwilling to use during the trial; Patients who are planning pregnancy within 1 month after the completion of the trial (including male patients);
  9. Potential difficult airway or difficult tracheal intubation, as determined by the investigator, and/or history of intubation failure;
  10. Patients determined by the investigator to be unsuitable for participating in this trial for any reason.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    HSK3486

    0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg/kg, 0.5mg/kg

    Drug: HSK3486

  • Active comparator
    Propofol

    1.0mg/kg, 2.0mg/kg

    Drug: Propofol

Interventions

  • For induction and maintenance of sedation.

  • For induction and maintenance of sedation.

06

What researchers measure

Primary outcomes

  1. Rate of successful colonoscopies.

    Time frame: From the first dose of the study drug to removal of colonoscope on day 1

Secondary outcomes

  1. Insertion time

    Time frame: From the first dose of study drug until insertion of colonoscope on day 1

  2. The success rate of the colonoscopy procedure

    The number of patients who successfully completed the colonoscopy procedure accounted for the proportion of all patients in the dose group

    Time frame: From the first dose of the study drug to removal of colonoscope on day 1

  3. Time to fully alert

    Time frame: From the removal of colonoscopy procedure, until the first of three consecutive MOAA/S scores of 5 on day 1

  4. Time to discharge

    Time frame: From the removal of colonoscopy procedure, until the first of three consecutive MOAA/S scores of 9 on day 1

  5. Application of study drug and alternative medication

    Total dosages of study drug and alternative medication

    Time frame: During the colonoscopy procedure on day 1

  6. Mini-Mental State Examinations (MMSE)

    Time frame: During the screening and the colonoscopy procedure on day 1

07

Study locations

1 site
  • West China Hospital, Sichuan University
    Chengdu, Sichuan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Jun 2017, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2018
First posted
Dec 12, 2018
StartActual
Dec 2016
Primary completionActual
Jun 2017
CompletionActual
Jun 2017
Last update
Dec 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03773042
Responsible party
Sponsor
First posted
Dec 12, 2018
Start date
Dec 2016
Primary completion
Jun 2017
Completion
Jun 2017
Last update
Dec 13, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion